PMID- 31094457
OWN - NLM
STAT- MEDLINE
DCOM- 20190701
LR  - 20190701
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 91
IP  - 3
DP  - 2019 Mar 30
TI  - Clinical efficacy of acute respiratory viral infections prevention in patients 
      with chronic heart failure.
PG  - 36-41
LID - 10.26442/00403660.2019.03.000111 [doi]
AB  - AIM: The aim of the study was to evaluate the ARVI prevention effectiveness in 
      patients with chronic heart failure (CHF) using interferon inducer amixin. 
      MATERIALS AND METHODS: Conducted a comprehensive survey, dynamic monitoring and 
      treatment of 60 patients aged from 49 to 70 years (mean age 60.25+/-4.57 years, 17 
      men and 43 women) with CHF with preserved ejection fraction of left ventricle 
      (LVEF) (>/=50%), II-III functional class (FC) according to the classification of 
      new York Heart Association (NYHA), which developed as a result of coronary heart 
      disease (CHD), hypertensive disease (HD). Of these, 30 patients (group 1) on the 
      background of standard therapy for CHF received for the prevention of ARVI 
      tiloron (Amixin) at a dose of 125 mg once a week for 6 weeks, two courses for 1 
      year. Group 2 patients received only standard therapy for CHF. RESULTS: A 
      decrease in the frequency of ARVI in patients with CHF treated with Amixin was 
      found, which was accompanied by a decrease in the severity of subclinical 
      inflammation by reducing the production of proinflammatory (IL-1beta) and increasing 
      the production of anti-inflammatory (IL-10) cytokines, reducing neurohumoral 
      activation (reducing levels of aldosterone and Nt-proBNP), increasing the level 
      of alpha- and gamma-interferon. The positive dynamics of biomarkers of systemic 
      inflammation and neurohormonal activation explains the improvement of the 
      clinical course in patients with CHF (increase of tolerance to physical loads, 
      reducing the number of visits to General practitioner and hospital admissions in 
      the hospital during 12 months of observation). CONCLUSION: A promising approach 
      to the prevention of SARS in patients with CHF is course therapy with Amixin (2 
      times a year before the seasonal rising in the incidence of respiratory viral 
      infections and influenza), which allows to achieve both decreasing in the 
      frequency of SARS per year, and improvement the clinical course of CHF.
FAU - Budnevsky, A V
AU  - Budnevsky AV
AD  - Voronezh State Medical University of the Ministry of Health of the Russian 
      Federation, Voronezh, Russia.
FAU - Shurupova, A D
AU  - Shurupova AD
AD  - Voronezh State Medical University of the Ministry of Health of the Russian 
      Federation, Voronezh, Russia.
FAU - Kravchenko, A Ya
AU  - Kravchenko AY
AD  - Voronezh State Medical University of the Ministry of Health of the Russian 
      Federation, Voronezh, Russia.
FAU - Tokmachev, R E
AU  - Tokmachev RE
AD  - Voronezh State Medical University of the Ministry of Health of the Russian 
      Federation, Voronezh, Russia.
LA  - eng
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Antiviral Agents)
RN  - O6W7VEW6KS (Tilorone)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Antiviral Agents/*administration & dosage
MH  - Chronic Disease
MH  - Female
MH  - Heart Failure/*physiopathology
MH  - Heart Ventricles
MH  - Humans
MH  - Hypertension/*complications
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Infections/*prevention & control/virology
MH  - Tilorone/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - acute respiratory viral infections
OT  - chronic heart failure
OT  - cytokines
OT  - tiloron
EDAT- 2019/05/17 06:00
MHDA- 2019/07/02 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/07/02 06:00 [medline]
AID - 10.26442/00403660.2019.03.000111 [doi]
PST - ppublish
SO  - Ter Arkh. 2019 Mar 30;91(3):36-41. doi: 10.26442/00403660.2019.03.000111.